# Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

> **NCT01088529** · PHASE2 · COMPLETED · sponsor: **Cougar Biotechnology, Inc.** · enrollment: 66 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Abiraterone Acetate
- **DRUG:** Prednisone
- **DRUG:** LHRHa

## Key facts

- **NCT ID:** NCT01088529
- **Lead sponsor:** Cougar Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2014-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01088529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01088529, "Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01088529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*